7MZF

SARS-CoV-2 receptor binding domain bound to Fab PDI 37

Summary for 7MZF

• Entry DOI: 10.2210/pdb7mzf/pdb
• Descriptor: Spike protein S1, PDI 37 heavy chain, PDI 37 light chain, ... (8 entities in total)
• Functional Keywords: sars-cov-2, spike, rbd, human antibody, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2); More
• Total number of polymer chains: 3
• Total formula weight: 71462.01

Authors

Pymm, P.,Chan, L.J.,Dietrich, M.H.,Tan, L.L.,Tham, W.H. (deposition date: 2021-05-24, release date: 2021-10-06, Last modification date: 2024-11-13)

Primary citation

Wheatley, A.K.,Pymm, P.,Esterbauer, R.,Dietrich, M.H.,Lee, W.S.,Drew, D.,Kelly, H.G.,Chan, L.J.,Mordant, F.L.,Black, K.A.,Adair, A.,Tan, H.X.,Juno, J.A.,Wragg, K.M.,Amarasena, T.,Lopez, E.,Selva, K.J.,Haycroft, E.R.,Cooney, J.P.,Venugopal, H.,Tan, L.L.,O Neill, M.T.,Allison, C.C.,Cromer, D.,Davenport, M.P.,Bowen, R.A.,Chung, A.W.,Pellegrini, M.,Liddament, M.T.,Glukhova, A.,Subbarao, K.,Kent, S.J.,Tham, W.H.
Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain.
Cell Rep, 37:109822-109822, 2021

PubMed Abstract: Potent neutralizing monoclonal antibodies are one of the few agents currently available to treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the viral spike protein can exhibit neutralization resistance, potentially affecting the effectiveness of some antibody-based therapeutics. Here, the generation of a diverse panel of 91 human, neutralizing monoclonal antibodies provides an in-depth structural and phenotypic definition of receptor binding domain (RBD) antigenic sites on the viral spike. These RBD antibodies ameliorate SARS-CoV-2 infection in mice and hamster models in a dose-dependent manner and in proportion to in vitro, neutralizing potency. Assessing the effect of mutations in the spike protein on antibody recognition and neutralization highlights both potent single antibodies and stereotypic classes of antibodies that are unaffected by currently circulating VOCs, such as B.1.351 and P.1. These neutralizing monoclonal antibodies and others that bind analogous epitopes represent potentially useful future anti-SARS-CoV-2 therapeutics.

PubMed: 34610292
DOI: 10.1016/j.celrep.2021.109822

Experimental method

X-RAY DIFFRACTION (2.493 Å)